Caenorhabditis Intervention Testing Program (CITP) at the University of Oregon

项目摘要 与人类老龄化相关的健康挑战给我们的社会带来了巨大的损失。物理和 认知能力下降限制了老年人及其照顾者的生活质量。老龄化是主要的 癌症、糖尿病和神经退行性疾病的风险因素和可能原因，因此 与使人衰弱的疾病作斗争是老龄化人口的共同健康负担。没有 问题，促进健康老龄化与延长抗衰退应该是一个主要的 当前医学研究的目标。 为了研究健康衰老，简单的动物模型，如线虫C。优雅的有 研究，为基因和化学化合物干预提供分子见解 可以调节保守的衰老过程，可能在人类中起类似作用。的目标 拟议的工作是继续并扩大一个合作科学小组的努力， 三个密切互动的实验室，他们协调测试药物干预， 能够延长线虫的健康衰老和促进长寿。特别强调的是， 一个综合的超级小组将在一组天然变异体上测试有希望的药物。 隐杆线虫属，它们共同代表了广泛的遗传异质性， 人口。这个想法是，在不同的环境中产生积极结果的治疗， 种群将有更大的机会在高等生物中有效， 建议作为临床前小鼠研究和未来可能的测试的优先干预措施 人体试验 该提案的重点是评估CITP以前设立的多样性小组， 建立了调查内部和之间的菌株变异的来源，包括可能的食物 通过复合相互作用，并使用一组基因表达标记来识别遗传 作为化合物的作用靶标的途径， 项目 总的来说，我们将参与一个独特的团队项目， 药理干预，在不同的环境中， 人口，与促进健康的人类衰老的疗法的发展的影响。

Project Summary Health challenges linked to human aging take a tremendous toll on our society. Physical and cognitive decline limit the quality of life for the elderly and their caregivers. Aging is the major risk factor for, and possible cause of cancer, diabetes, and neurodegenerative disease, and thus struggle with debilitating disease is a common health burden for the aging population. Without question, the promotion of healthy aging with extended resistance to decline should be a major objective of current medical research. To investigate healthy aging, simple animals models such as the nematode C. elegans have been studied, providing molecular insights into the genes and chemical compound interventions that can modulate conserved aging processes likely to act similarly in humans. The goal of the proposed work is to continue, and expand, efforts of a co-operative scientific group involving three closely interacting laboratories who coordinately test pharmacological interventions for the ability to extend healthy aging and promote longevity in nematodes. A specific emphasis of this integrated super-group is to test promising drugs on a collection of natural variants of the Caenorhabditis genus, which together represent the extensive genetic heterogeneity in the human population. The idea is that treatments that confer positive outcomes across a diverse population will have an increased chance of being efficacious in higher organisms and will be suggested as priority interventions for testing in pre-clinical mouse studies and possibly future human trials. The emphasis of this proposal is to evaluate the diversity panel that the CITP has previously established to investigate sources of within and between strain variation, including possible food by compound interactions, and to use a panel of gene expression markers to identify genetic pathways that serve as targets of action for compounds identified during the testing phase of the project. Overall, we will participate in a unique team project that has the power to define pharmacological interventions that robustly promote strong healthspan across a varied population, with implications for development of therapies that promote healthy human aging.